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Abstract Proteomics refers to the study of the entire set
of proteins in a given cell or tissue. With the extensive
development of protein separation, mass spectrometry, and
bioinformatics technologies, clinical proteomics has shown
its potential as a powerful approach for biomarker dis-
covery, particularly in the area of oncology. More than 130
exploratory studies have defined candidate markers in
serum, gastrointestinal (GI) fluids, or cancer tissue. In this
article, we introduce the commonly adopted proteomic
technologies and describe results of a comprehensive
review of studies that have applied these technologies to GI
oncology, with a particular emphasis on developments in
the last 3 years. We discuss reasons why the more than 130
studies to date have had little discernible clinical impact,
and we outline steps that may allow proteomics to realize
its promise for early detection of disease, monitoring of
disease recurrence, and identification of targets for indi-
vidualized therapy.
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The term ‘‘proteome,’’ coined in 1995, is analogous to
‘‘genome,’’ and was initially used to describe ‘‘the entire
complement of proteins expressed by a genome, cell, tissue
or organism’’ [1]. The human genome contains about 23,000
protein-coding genes [2], but because of the occurrence of
alternative splicing, the proteome is much larger, and
probably consists of more than 100,000 distinct polypep-
tides [3]. The prevalence of post-translational modifications
contributes additional diversity. Proteomic analysis is more
challenging than genomic analysis, but is also more
rewarding, because it captures regulatory effects at all levels
of gene expression (i.e., transcriptional, translational, and
post-translational). The goal of proteomics, in most cases, is
the discovery of protein biomarkers, which are signatures of
physiological or disease state. These can be used, alone or in
combination, for screening and diagnosis, establishment of
individual prognosis, prediction of individual response to
therapy, and monitoring of disease progression [4, 5].
This review is in three parts. First, we present an over-
view of current proteomic technologies. Proteins and
peptides are much more chemically diverse than nucleic
acids, and the technologies required for proteome analysis
are correspondingly more complex. It is helpful to intro-
duce terminology and current technical approaches before
considering clinical studies in detail. Second, we describe
the use of proteomic technologies in GI oncology. This
compilation is based on a MEDLINE search of the
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literature through August 2008. In addition to summarizing
our results in table form, we provide an overview and
briefly summarize a few notable findings in the main text.
Third, we discuss prospects for application of proteomic
findings in GI oncology, including the limitations of cur-
rent studies and a discussion of steps that are needed to
advance the field to the next level.
Proteomic Technologies
Figure 1 provides an overview of currently available ana-
lytical strategies, including types of samples and profiling
methods.
Types of Samples
Samples used for clinical proteomics come from three
sources: serum, other accessible body fluids (e.g., saliva,
gastric juice, pancreatic juice, or bile), and tissue. Serum is
advantageous for screening and early detection of disease
because collection is minimally invasive. It presents chal-
lenges for analysis, however, because cancer biomarkers
are likely to be much more dilute in serum than in the
tissue of origin. An additional complication is that a
majority of serum peptides likely represent fragments of
larger proteins degraded by various proteases [6]. GI fluids
are advantageous because they are relatively organ-spe-
cific, and proteins of interest may be present at higher
Fig. 1 Strategies for proteomic analysis of clinical samples. Samples
may include serum, other body fluids, or tissue. Profiling may be
antibody-based or MS-based. A variety of labeling and protein
separation techniques may be used prior to the MS. Top-down and
bottom-up approaches differ in the order in which steps are performed.
In many proteomic studies, key findings are validated by independent
means (see text for details and definition of additional terms)
Fig. 2 LCM. a Thermoplastic membrane is placed over a tissue
section, b infra-red laser pulse is used to heat a 7.5–30 lm diameter
spot, briefly melting the membrane and capturing cells of interest.
Heating and cooling of the membrane apparently has no adverse
effect [7]. c Cells of interest become attached to the membrane and
can be lifted from the slide for downstream analysis. d Application of
LCM on colonic epithelium and colon cancer tissue slides
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concentrations than those in the serum. Because collection
is difficult and somewhat invasive, analysis of GI fluids is
an option that is primarily applicable in symptomatic
patients. Tissue samples are advantageous because tissue is
the ultimate source of biomarkers present in serum and
other fluids. Although collection is invasive, tissue
extraction provides access to a variety of intracellular
regulatory proteins, such as regulatory kinases or tran-
scription factors, which would not routinely be present in
serum or GI fluids. Tissue studies thus may provide more
insight into disease mechanisms than can be obtained by
analysis of samples from non-tissue sources.
Tissue proteomics may use material from bulk dissec-
tion or laser capture microdissection (LCM). The latter,
illustrated in Fig. 2, allows analysis of specific cell types
(e.g., cancer cells free of stroma) [7]. Other methods of
sample fractionation have also been used to enrich for
cancer cells, for example passage through a narrow gauge
needle to detach tumor cells from stroma [8]. Tissue pro-
teomics can also be performed using imaging mass
spectrometry (IMS), where tissue sections are analyzed
directly by mass spectrometry, circumventing the need for
microdissection or protein extraction (recently reviewed in
[9]).
Use of archival tissue is complicated by covalent protein
modifications introduced by common methods of fixation
and staining. Although several recent reports describe
analysis of peptides recovered from formalin-fixed, paraf-
fin-embedded tissues [10–13], the most common method of
sample preservation for proteomic analysis is freezing,
which necessitates dedicated sample collection. Alternative
techniques based on alcohol or other chemical fixatives
have also shown promise [14, 15].
Profiling Methods
Mass Spectrometry (MS)-Based Profiling
Many clinical studies are exploratory, that is, broad surveys
of the proteome without prior knowledge of the proteins of
interest. Profiling of tissue extracts can be performed using
either a ‘‘top-down’’ or ‘‘bottom-up’’ approach (Fig. 1).
Top-down approaches begin with one or more separation
steps to resolve individual proteins, or classes of proteins,
in a complex mixture. Because intact proteins are physi-
cally and chemically diverse, there is no single universally
applicable separation method. Two-dimensional gel elec-
trophoresis (2-DE), which separates proteins based on
charge in one dimension and size in the other [16], can
separate up to 5,000 distinct proteins simultaneously [17].
Proteins may be reacted with fluorescent CyDyes prior to
electrophoresis, or the gel may be stained afterward.
Limitations of 2-DE are that it cannot be fully automated,
and tends not to resolve proteins that are large, hydro-
phobic, or strongly basic. Liquid chromatography (LC)
provides an alternative to 2D gels; although it can be used
for intact proteins, it has found wider application in the
‘‘bottom-up’’ approaches discussed below.
Surface adsorption is a specialized separation and con-
centration method used in surface enhanced laser desorption
ionization (SELDI). A protein solution is incubated with a
hydrophobic, charged, or other surface that is fabricated as
part of a chip that can be introduced directly into a mass
spectrometer, producing a complex mass spectrum that
provides a ‘‘fingerprint’’ of a physiological state or disease.
SELDI is easily applied to large numbers of clinical samples
and is most commonly used for serum studies.
In a bottom-up approach, the order of the analytical
steps differs [18, 19]. Proteins in the sample mixture are
first digested to completion with a site-specific protease.
Peptides (rather than intact proteins) are chromatographi-
cally separated by high-resolution ion exchange and
reverse-phase LC. Products are again analyzed by MS in
the final step [20]. Although throughput is limited, bottom-
up approaches can identify very large numbers of proteo-
mic features, and they can be applied to proteins that are
difficult to solubilize and resolve when intact [21]. Top-
down and bottom-up approaches are thus complementary
and potentially provide somewhat different information.
Options for final MS analysis are similar in all approa-
ches. A ‘‘soft ionization’’ procedure creates peptide ions in
the gas phase, using mild conditions that maintain peptide
bonds intact. In matrix-assisted laser desorption ionization
(MALDI) (and its specialized variations, SELDI and IMS)
a laser pulse is directed at a mixture of protein sample and
an organic matrix (Fig. 3a) [22]. With electrospray ioni-
zation (ESI), the other common soft ionization method, a
protein or peptide solution passes through a heated capil-
lary, spraying droplets of solution into a vacuum chamber
containing a strong electric field, where they then evapo-
rate and ionize (Fig. 3b) [23]. The ions are passed through
a mass analyzer, which separates them based on mass-to-
charge (m/z) ratio.
Data is obtained in the form of a mass spectrum—a
histogram with ion counts on the vertical axis and m/z on
the horizontal axis (Fig. 3). In SELDI, pattern analysis may
be applied to detect features of the spectrum that correlate
with disease state, even without identification of proteins at
the molecular level. In other MS procedures, the goal is
molecular identification of proteins present in the sample.
This is done by matching a pattern of peptides, or ‘‘peptide
mass fingerprint,’’ against a human protein database.
Confidence in MS identifications is based on coverage (the
fraction of the protein’s total sequence represented among
the identified peptides) and statistical criteria particular to
the method used.
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Tandem mass spectrometers, which have more than one
mass analyzer connected in series, can perform MS/MS.
This involves selection of an ion of interest based on m/z,
partial fragmentation at peptide bonds (by collision with an
inert gas), and passage of the products through a second
mass analyzer, with the resulting fragmentation pattern
providing amino acid sequence information for the pre-
cursor ion. Partial sequence data obtained by MS/MS
provides a further basis for identification [24].
Imaging MS is performed by first coating a thin (10-lm)
tissue section with organic matrix. The section is system-
atically moved underneath a laser beam and a mass
spectrum is collected at each position. Software renders the
data as a spatially resolved density map showing relative
abundance of peptides or proteins of interest [9, 25].
Quantification of Protein Abundance
Clinical laboratory studies require quantification of
molecular species, rather than simple determination of
presence or absence. Neither gel staining nor mass spec-
trometry provides a good indication of absolute quantity.
Quantification thus relies on multiplex analysis, where
samples from different sources are differentially labeled,
mixed, and subjected to electrophoretic or chromatographic
separation. The abundance of each protein or peptide is
determined relative to the corresponding feature in the
other sample. Clinical samples can be compared directly
(e.g., diseased versus normal) or indirectly with reference
to an invariant internal standard, consisting of a mixture of
samples used in the experiment.
Two-dimensional difference gel electrophoresis (2D-
DIGE) is the most common multiplex top-down approach
[26, 27] (Fig. 4). Proteins are covalently labeled by reac-
tion of cyanine dyes with cysteine or lysine residues.
Spectrally distinct dyes are similar in molecular weight and
do not change the protein charge. Thus, the same proteins
in different samples, labeled in different colors, migrate to
the same position in the gel. For each spot, the ratio of
emission at different wavelengths provides a measure of
relative abundance [28].
Isotope-coded affinity tag (ICAT) technology is the
analogous method for the bottom-up approach. The ICAT
reagent combines three moieties: a biotin group, a heavy or
light isotope-tagged linker (e.g., containing 2H vs. 1H, or
13C vs. 12C), and a thiol-specific reactive group that reacts
with cysteine in the protein sample (Fig. 5a) [29]. Two
samples, pre-labeled with heavy- or light-isotope ICAT
reagent, are mixed and proteolytically digested (Fig. 5b).
Tagged peptides are isolated by avidin affinity
Fig. 3 MALDI-MS and ESI-MS procedures. a In MALDI-MS,
samples are co-crystallized with an organic matrix on a metal target
plate. A pulsed laser irradiates the co-crystals, which causes rapid
heating and desorption of ions into the gas phase. Ions go through the
mass analyzer and the detector registers the numbers of ions at each
individual mass-to-charge (m/z) value, then the peptide mass
fingerprint is generated. MALDI-MS produces relatively simple
spectra composed of ions with unit charge. b In ESI-MS, sample
molecules are ionized directly in the analyte solution by passing
through a heated capillary device, spraying droplets of solution into a
vacuum chamber containing a high-strength electric field. The
resulting ions pass through a mass analyzer and detector as in a.
ESI-MS produces complex spectra with multiply charged ions
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chromatography and analyzed by LC-MS [30]. The relative
abundance of heavy and light isotope peaks for each pep-
tide provides an accurate measure of the relative abundance
of the peptide in different samples. A variation, isotope-
coded protein label (ICPL) [31], is based on isotopic
labeling of free amino groups in proteins, which are more
abundant than thiols. Another variation, isobaric tags for
relative and absolute quantification (iTRAQ) allows mul-
tiplexing of up to four samples simultaneously [32].
Antibody-Based Profiling
In contrast to MS-based methods, antibody-based profiling
requires prior knowledge of proteins of interest. Tissue
microarrays exemplify a broad class of technologies
referred to as protein arrays where proteins or tissue sam-
ples are spotted on a surface and probed with antibody
(Fig. 6a) [33, 34]. Often used for validation of biomarkers




gel images of proteins from
analysis of a microdissected
CRC specimen in our
laboratory. Red represents Cy5-
labeled sample proteins, and
green represents Cy3-labeled
pooled internal standard. In the
multiplexed image, spots that
are more abundant in the sample
than in the standard appear red,
spots that are less abundant in
the sample appear green, and
spots that are equal in the
sample and the standard appear
yellow. b Design of a clinical
proteomics experiment. In this
example, which is based on
analysis of cancer-normal pairs,
each patient contributes two
samples: cancer and adjacent
normal tissue. The number of
gels equals the number of
samples. For each spot in each
gel, the ratio of emission at Cy5
and Cy3 wavelengths is
measured. These ‘‘internal
ratios’’ are used to compare the
relative abundance of a given
protein across the different
specimens in the experiment
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advantages and disadvantages as other forms of immuno-
histochemistry (IHC). Interpretation of staining patterns
can be subjective, and quantification is less precise than
with other proteomic methods [35].
In another variation on array technology, a panel of
antibodies is spotted on a surface and incubated with a
solubilized mixture of proteins. After washing, the protein
bound to each spot is quantified using a labeled secondary
antibody or reagent (Fig. 6b) [36]. The technology of
antibody arrays is just beginning to be applied in GI
oncology [37, 38] and holds promise as a method for
simultaneous analysis of multiple biomarkers, or ‘‘proteo-
mic signatures’’ in a clinical laboratory setting.
Use of Proteomic Technologies in GI Oncology
Methods
To identify relevant literature, we searched MEDLINE
through August 2008 using entry terms including ‘‘pro-
teomics,’’ ‘‘biomarker discovery,’’ ‘‘mass spectrometry,’’
‘‘gastrointestinal tumor,’’ ‘‘serum,’’ ‘‘human tissue,’’
‘‘gastric juice,’’ ‘‘pancreatic juice,’’ ‘‘bile,’’ ‘‘GI secre-
tions,’’ ‘‘esophageal cancer,’’ ‘‘gastric cancer,’’ ‘‘small
intestine tumor,’’ ‘‘colorectal cancer,’’ ‘‘pancreatic cancer,’’
‘‘hepatocellular carcinoma,’’ and ‘‘cholangiocarcinoma’’ in
different combinations. English-language abstracts of the
retrieved articles were reviewed and categorized. In all but
a few cases, full articles were obtained and reviewed.
Additional citations were obtained from review articles and
from the bibliographies of cited references.
Serum Biomarkers
We identified 57 serum-based studies (Table 1). Of these,
54 used MS-based profiling, while three recent studies
applied antibody-based profiling [37–39]. All but one of
the MS-based studies used a ‘‘top-down’’ strategy, in the
majority of cases SELDI-MS (38/54 studies).
Diseases of the Alimentary Tract
Eight studies analyzed sera from patients with esophageal
cancer or related premalignant conditions such as dysplasia
or basal cell hyperplasia. In three of these, anonymous
SELDI m/z peaks were used in classification algorithms to
discriminate between normal or disease states [40–42]. In a
fourth SELDI study, m/z peaks were used to distinguish
chemoradiation responders from non-responders [43]. Two
2-DE studies identified a small number of serum proteins
that differed in pre- and post-surgery patients, with no
overlap in the proteins identified in the two reports [44, 45].
Two other studies identified characteristic serum autoanti-
bodies against peroxiredoxin VI and heat-shock protein 70,
respectively, as potential diagnostic biomarkers [46, 47].
Five studies of gastric cancer have used the SELDI
approach [48–52]. In each case, SELDI identified combi-
nations of m/z peaks that correctly classified most cancer
patients versus other subjects. In one study, relevant peaks
were identified as stress-related proteins, including heat-
shock protein 27, glucose-regulated protein, and protein
disulfide isomerase [50]. Levels of these proteins declined
following surgery, suggesting that they could be used in
Fig. 5 Schematic illustration of ICAT procedure. a ICAT reagent
combines three moieties: a biotin tag, a heavy or light isotope-tagged
linker, and a thiol-specific reactive group. b Samples, labeled with
heavy- or light-isotope ICAT reagent are mixed and digested. Tagged
peptides are isolated by avidin affinity chromatography and analyzed
by LC-MS. The relative abundance of heavy and light isotope peaks
for each peptide is then measured. Peptides of interest can be
identified by MS/MS analysis
436 Dig Dis Sci (2009) 54:431–457
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surveillance for recurrence [50]. Specificity and sensitivity
using SELDI-based biomarkers were higher than those
achieved for the same samples using two established
markers, carcinoembryonic antigen (CEA) and carbohy-
drate antigen (CA) 19–9, in combination [52]. A very recent
study used antibody microarray technology to explore
serum biomarkers of gastric cancer. Serum reactivity with
IPO-38 antibody, which is directed against a small nuclear
protein (possibly H2B), appeared useful both for diagnosis
and for predicting survival in gastric cancer [38].
Ten studies analyzed sera from colorectal cancer (CRC)
patients. Nine used SELDI-MS; several showed that
SELDI-MS biomarkers compare favorably with established
tests, including fecal occult blood or CEA [53], or a triple
combination of CEA, CA19–9, and CA 242 [54]. SELDI-
MS markers can be used to classify different stages of CRC
[55], and to differentiate between good and poor respond-
ers to neoadjuvant therapy [56]. As with other diseases, the
majority of CRC SELDI-MS studies are based on anony-
mous peaks, although a few studies report identification of
specific proteins associated with classifier peaks, including
apolipoproteins A-I and C-I [57], complement C3a des-arg,
alpha1-antitrypsin and transferrin [53], and serum amyloid
A [58]. A 2-DE serum analysis found 28 spots differen-
tially expressed between cancer and normal, among which
clusterin, complement factor I and b-2-glycoprotein I were
proposed as a potential panel of CRC biomarkers [59].
Although most studies focus on cancer, three used
proteomic methods to identify biomarkers of benign dis-
eases [60–62]. One of these studies showed the ability to
distinguish patients with Crohn’s disease or ulcerative
colitis from control subjects who were either healthy or
suffered from other inflammatory conditions based on four
identified classifier proteins [60]. Another showed the
ability to identify patients with large colon adenomas based
on a set of anonymous m/z peaks [62]. Another used ICAT
technology to identify proteins useful for differential
diagnosis of familial adenomatous polyposis [61].
Diseases of the Pancreas and Hepatobiliary Tract
Ten studies profiled sera from pancreatic or biliary tract
cancer patients. Three SELDI studies identified anonymous
m/z peaks that correctly classified most pancreatic cancer
[63, 64] or cholangiocarcinoma [65] patients. In one of these
studies, SELDI-MS biomarkers, or SELDI-MS biomarkers
in combination with CA19-9, were significantly more
accurate than CA19-9 alone [63]. Serum CA 19-9 can also be
sensitively detected with protein array technology [39].
Other studies, using 2-DE, identified proteins, or in one case
autoantibodies, that are differentially present in sera from
cancer patients versus control subjects [66–69]. In one of the
first applications of antibody microarray to GI oncology, a
recent study identified a signature consisting of 21 protein
analytes that discriminates between short-surviving (\12
months) and long-surviving pancreatic cancer patients [37].
Twenty studies, primarily using SELDI-MS, character-
ized changes in the serum proteome of patients with
hepatocellular carcinoma (HCC). HCC usually develops
following a long history of chronic liver disease, and there is
a need for markers of progression to cancer. All SELDI
studies identified m/z peaks that accurately classified sera
from patients with chronic hepatitis B or C infection,
cirrhosis, and HCC (Table 1). Two studies specifically
commented on prospects for use of SELDI-MS biomarkers
for early detection: Kanmura et al. analyzed sera collected
before the diagnosis of HCC by ultrasonography. They
demonstrated the ability of SELDI-MS biomarkers to predict
the diagnosis of HCC in 6/7 patients before HCC was clin-
ically apparent [70]. Zinkin et al. demonstrated that SELDI-
Fig. 6 Protein microarray technology. a Tissue microarray. Multiple
tissue sections (or protein extracts) are spotted onto an array, which is
incubated with a specific antibody against the protein of interest.
Samples that contain the protein of interest are then detected. b
Antibody microarrays: A series of capture molecules (antibodies) are
displayed on a slide or membrane that is exposed to analytes (a tissue
lysate). The bound proteins are detected by labeled secondary
antibodies
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MS biomarkers were more accurate than traditional markers
in detecting small HCCs in Hepatitis C patients [71]. A 2-D
liquid phase fractionation study, using chromatofocusing
(similar to the first dimension of 2-DE but performed in
solution) and reverse-phase LC, identified 14 proteins
with differential expression in HCC, albeit based on a
single patient per group [72]. Another recent study identi-
fied a characteristic autoantibody signature in HCC patients
[73].
Prospects for Clinical Translation of Serum Biomarkers
When multiple studies of the same disease are compared, a
major limitation of serum profiling becomes evident, which
is the unsatisfactory reproducibility between studies. The
majority of early serum studies used SELDI technology,
resulting in identification of anonymous discriminatory m/z
peaks. In only a very few cases were the same discrimina-
tory peaks identified. This may well reflect technical
differences in sample collection, processing, type of SELDI
chip, or other variables. Inconsistency between studies,
however, is a major barrier to clinical translation of SELDI
biomarkers. In the minority of instances where m/z peaks
have been identified at the molecular level, many of them
correspond to high abundance, seemingly nonspecific
molecules such as stress proteins, clotting factors, and other
known serum components. Although tests based on these
markers might be clinically useful, it is disappointing that
markers have not been identified with a more obvious
connection to biological mechanisms of cancer develop-
ment. One reason for this, suggested by Diamandis [74], is
that current SELDI-TOF technology is capable of detecting
only those proteins present at a concentration greater than
1 lg/ml, which is approximately 1,000-fold greater than
the concentrations of established serum tumor markers
(e.g., CEA). Very recently, newer technologies such as
ICAT and protein arrays have begun to be applied in serum
studies, and it is possible that these may overcome some of
the limitations of earlier methodologies.
A potentially difficult issue is that most serum studies
relied on patients with advanced disease, where host-tumor
(paraneoplastic) interactions are likely to be prominent.
Serum biomarkers discovered thus far may not be appli-
cable for early detection of cancer in the general, low-risk
population, which is typically a stated goal in serum
studies. A more immediate application of serum-based
biomarkers may be for differential diagnosis in symptom-
atic patients or monitoring of disease progression and
treatment responses following diagnosis. If issues of stan-
dardization and reproducibility can be overcome, accuracy
in the various studies cited here ([80% sensitivity and
specificity) seems well within the range that would be
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Biomarkers from GI Secretions
Biological fluids have a special role in proteomics as
applied to GI oncology. The GI tract is unique among
organ systems because of the amount and type of secre-
tions. The normal adult produces about 7 l of GI fluids
daily, including saliva, gastric juice, pancreatic juice, bile,
and enteric secretions [75]. These are secreted and reab-
sorbed in balance. Fluids produced by the GI tract have
less-complex compositions than serum, are relatively
organ-specific, and are potentially good sources for bio-
marker discovery.
There have been two ‘‘top-down’’ 2-D gel-based pro-
teomic profiling studies of gastric juice. These reported
simple changes in proteomic pattern that differentiate
cancer, precancerous conditions and benign disease,
including loss of gastric digestive enzymes and appearance
of a1-antitrypsin-related proteins [76, 77] (Table 2).
A SELDI-MS study by Rosty et al. [78] dramatically
demonstrated the advantages of using pancreatic juice over
serum for detection of pancreatic adenocarcinoma markers.
They showed that hepatocarcinoma-intestine-pancreas/
pancreatitis-associated-protein-1 (HIP/PAP-1) was present
at 1,000-fold higher levels in pancreatic juice of cancer
patients than in the serum of the same individuals. The fold
difference in cancer patients versus other subjects was also
much higher in pancreatic juice than in serum. Studies by
Chen et al. [79, 80] used ‘‘bottom-up’’ ICAT and tandem
MS-based proteomics to compare protein expression in
pancreatic juice from cancer, chronic pancreatitis, and nor-
mal tissue. They identified 30 proteins specific to cancer, 27
specific to chronic pancreatitis, with nine in common. Three
studies using ‘‘top-down’’ gel-based separations identified
numerous potential cancer biomarkers, some of which were
known and others of which were novel, including a HIP/
PAP-1-related protein designated as PAP-2 [81–83].
Three studies characterized bile from patients with
cholangiocarcinoma. Kristiansen et al. [84] used lectin
chromatography to enrich for proteins of interest and
deplete interfering proteins, facilitating analysis of the
glycoproteome. Eighty-seven unique proteins were identi-
fied and 33 glycosylation sites were found. Two studies
[85, 86] analyzed the proteomes of bile fluid from patients
with malignant and benign bile tract obstruction using 2-
DE; in one study, the pancreatic elastase/amylase ratio was
confirmed to be a much more accurate marker than CEA or
CA 19-9 [86].
Prospects for Clinical Translation of GI Secretions
Biomarkers
Together, studies confirm the promise of GI secretions as a
concentrated source of potentially useful biomarkers.
Accessibility of these fluids varies, with collection of
gastric juice being considerably easier and less invasive
than pancreatic juice or bile. Nevertheless, fluids are rou-
tinely collected in symptomatic patients and tests based on
these fluids may therefore be practical.
Biomarkers from GI Tissue
Tissue biomarkers are useful when a sample of the diseased
tissue is available as a result of biopsy or surgical resection.
Biomarkers identified by proteomic profiling of tissue have
the potential to be useful directly, for example in staging or
prediction of response to therapy. Information gleaned
from tissue studies also lays a foundation for development
of clinical serum tests; for example, if proteomic profiling
reveals that a particular protein is present at high concen-
tration in tumor tissue, one might develop a more-sensitive
assay (based, for example, on protein-chip or other
approaches) to investigate the presence of the protein in
serum from cancer patients.
Diseases of the Alimentary Tract
There have been ten studies of esophageal cancer, all using
‘‘top-down’’ analysis. Eight used 2-DE separation, one
used chromatofocusing, and one used capillary high-per-
formance LC (Table 3). One of the most comprehensive of
all reported proteomic surveys of GI cancers, conducted by
Hatakeyama et al. [87], used 2D-DIGE to analyze 129
microdissected tissue specimens, which identified 217
differentially expressed proteins at the molecular level.
Thirty-three of these distinguished tumors with and without
nodal metastasis. Extensive bioinformatic analysis identi-
fied clusters of similarly regulated proteins, and gene
ontology analysis showed that differentially regulated
proteins had structural, transporter, chaperone, oxidore-
duction, transcription, and signal-transduction activities.
Zhao et al. [88] performed an interesting comparison of
protein and mRNA expression. Of 38 proteins that differed
in cancer-metaplasia pairs, mRNA correlated with protein
expression changes in some instances but differed mark-
edly in many others, underscoring the value added by
proteomic analysis.
There have been eight gastric cancer tissue studies, all
based on ‘‘top-down’’ analyses. Greengauz-Roberts et al.
[89] demonstrated the ability to profile very small amounts
of tissue (5 lg protein) using LCM and reported 42 proteins
with differential expression in gastric adenocarcinoma
versus spasmolytic peptide expressing metaplasia. He et al.
[90] identified an 18-kDa antrum mucosa protein that was
dramatically down-regulated in cancer tissues and proposed
a special role for this protein in pathogenesis of gastric
cancer. GI stromal tumor is a rare, non-epithelial
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malignancy of the GI tract, most commonly occurring in the
stomach. Many cases are associated with mutation of the
KIT protooncogene or platelet-derived growth factor
receptor alpha. Two 2-DE studies identified proteins that
were differentially expressed in patients in different muta-
tion classes, or that discriminated patients with poor and
good prognoses. Pfetin, a potassium channel protein, was
identified as a powerful prognostic marker [91].
Eleven reports describe proteomic profiling of CRC or
premalignant adenomas (Table 3). Seven studies using top-
down 2-DE approaches identified numerous differentially
expressed proteins including transcription regulators, signal
transduction, and cytoskeletal proteins, molecular chaper-
ones, protein synthesis factors, metabolic enzymes,
apoptosis-associated proteins, and a proteoglycan (mimec-
an). A study of Pei et al. [92] is notable for identifying four
proteins that differed specifically between primary tumors
derived from node-positive versus node-negative patients.
Two studies applied IMS technology on tissue sections
without solubilization or protein-separation steps, an
approach that is capable of providing spatially resolved
images of in situ protein abundance in tumor areas versus
normal areas [93, 94]. Another methodologically interesting
study by Madoz-Gurpide et al. [95] selected 29 gene prod-
ucts for detailed investigation based on statistically
significant up-regulation at the mRNA level and other cri-
teria. They expressed these gene products in E. coli,
prepared antibodies, and tested seven by IHC in a tissue
microarray. They confirmed that six (ANXA3, BMP4,
LCN2, SPARC, MMP7, and MMP11) were up-regulated at
the protein level. Their unique, gene- and antibody-based
approach avoids bias against interesting classes of proteins
(i.e., very large, hydrophobic, or insoluble) that are readily
overlooked in top-down proteomic approaches that rely on
2-DE as a first step.
Diseases of the Pancreas and Hepatobiliary Tract
Pancreatic cancer is second only to CRC as a cause of GI
cancer deaths in the US. Unlike CRC, it is almost never
detected until it has reached an incurable stage. Better
detection, together with insights into disease mechanisms
that might lead to better preventive or therapeutic options,
would bring a large public health benefit. There have been
seven ‘‘top-down’’ 2-DE studies (Table 3). The most com-
prehensive of these, by Lu et al. [96], identified 111
differentially expressed proteins at the molecular level.
Proteins in this and other studies have structural, protease,
metabolic, immune/inflammatory, transporter, RNA pro-
cessing, transcription factor, signal transduction, cell
adhesion, and other activities; some have been further val-
idated by IHC. Studies by Chen et al. [97, 98] used ‘‘bottom-
up’’ ICAT and tandem MS-based proteomics to identify 50
proteins as differentially expressed in cancer and 116 in
pancreatitis, with considerable overlap between groups.
Finally, A SELDI study [99] identified 33 anonymous m/z
peaks that collectively distinguished pancreatic cancer,
benign disease, and nonmalignant tissue. The same group
applied a similar methodology to cholangiocarcinoma and
identified 14 discriminatory, anonymous m/z peaks [65].
HCC is another GI cancer that has been widely studied
using tissue profiling. As in the serum studies, progression
of HBV or HCV-related disease to HCC has been the main
focus. Of 19 studies, 16 used ‘‘top-down’’ 2-DE approa-
ches, two used a ‘‘bottom-up’’ ICAT approach, and one
used direct analysis of tissue slices by SELDI-TOF. Two of
the most comprehensive studies combined LCM with
ICAT and 2D-LC-MS/MS to compare the proteome of
HCC with normal liver, identifying 149 differentially
expressed proteins in one case, and 261 in another [100,
101]. Blanc et al. [102] identified 155 differentially regu-
lated proteins in a 2-DE study, and Luk et al. [103],
identified 90 in another. A 2D-DIGE study identified 127
differentially expressed proteins in cancer, and demon-
strated in a validation study that a proteomic signature,
based on clathrin heavy chain and formiminotransferase
cyclodeaminase, could make substantial contributions to
early diagnosis of HCC [104].
A methodologically interesting study by Emadali et al.
[105] describes analysis of the hepatic tyrosine phospho-
proteome using anti-phosphotyrosine antibodies to enrich
for proteins of interest, followed by 1-DE and LC-ESI-MS/
MS analysis. Although the study focused on ischemia/
reperfusion (I/R) injury, the methodology could be readily
extended to HCC. They found that the tyrosine kinase
adaptor protein Nck-1 might play a role in I/R-induced
actin reorganization.
Identification of Site of Cancer Origin
Pathologists sometimes face the problem of identifying the
original site of a metastatic cancer when no primary tumor
has been identified. Bloom et al. [106] used 2-DE,
MALDI-TOF, and LC-MS/MS to compare the proteomic
profiles of 77 histologically similar adenocarcinomas aris-
ing from six different sites of origin. Using these data, a
neural network could correctly classify a single held-out
sample with an average predictive accuracy of 82%. These
findings show that proteomic data can be used to construct
an accurate classifier for tumors without knowledge of their
primary site of origin.
Prospects for Clinical Translation of Tissue Biomarkers
Almost every tissue proteomics study provides quantita-
tive expression values for at least a few hundred
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‘‘features’’—spots on a gel, m/z peaks, or linked sets of
peptides identified in bottom-up analysis. Among these
features, it is easy to find examples of proteins or other
features that show significant differential expression char-
acteristic of physiological or disease states. More than ten
independent studies have appeared for some tumor types
(i.e., CRC and HCC). However, lists of candidate bio-
markers produced in studies of the same tumor type are
often significantly different.
Some differences may be attributable to the distinctive
patient population seen at individual centers or by the
nature of the comparison sample (i.e., patient-matched
normal tissue, patients with benign disease, or ‘‘healthy’’
control subjects). There are also sources of variability that
are particular to proteomic analysis. Existing proteomic
profiling technology samples no more than 1% of the total
proteome, and different studies may sample a different 1%
depending on details of the methodology. Additionally, in
top-down studies, investigators choose only a fraction of
the total features as ‘‘interesting’’ enough for molecular
identification, and the criteria for selecting these features
vary. There are also significant differences in sample
preparation. Some studies (14/64) use microdissection or
other techniques to enrich for tumor cells, whereas the
majority use bulk specimens, where the tumor-cell specific
proteomic signature may be partially obscured by inter-
mixed host tissue.
Despite these sources of variability, some common
themes are evident, notably quantitative changes in cyto-
skeletal proteins, stress proteins, and enzymes of
intermediary metabolism. In addition to common and
abundant proteins, most studies report a few proteins that
seem ‘‘interesting’’ because they are potentially involved in
processes that drive malignancy, rather than simply
reflecting the malignant phenotype. These include tran-
scription factors, signal transduction proteins, and tumor
suppressors. Both types of markers are potentially valuable.
Quantitative changes in abundant proteins may have value
in establishing individual prognosis (e.g., changes in
cytoskeletal proteins that are predictive of metastatic
potential), whereas transcription factors and signaling
proteins may provide novel therapeutic targets.
Application of Proteomic Findings in GI Oncology
The number of exploratory proteomic studies in GI
oncology is astonishing: more than 130 to date. Given the
multiplicity of studies, have we moved closer to the ulti-
mate objectives of proteomic research? None of the
discoveries cited here has yet made a significant impact on
clinical care. Many barriers to clinical translation are evi-
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discover markers of early disease, the lack of overlap in
biomarkers identified in different studies of a same disease,
and lack of standardization in sample collection and stor-
age, protein-separation procedures, mass spectrometry, and
statistical methodology. Rapid evolution of MS technology
is a particularly significant contributor to lack of stan-
dardization, because studies performed at different times in
different institutions almost inevitably involve different
instrumentation.
Some progress has been made towards standardization,
at least in areas of sample preparation and analysis, as the
Early Detection Research Network of the US National
Cancer Institute provides the Standard Operating Proce-
dures and Assay Protocols for researchers via its Web site
(http://edrn.nci.nih.gov). At present, however, the content
of this resource remains limited.
Our review of published proteomic studies in GI
oncology has suggested to us several additional steps that
would be particularly valuable to the field:
– It is important that study design and patient selection
reflect the intended application of the markers. Markers
discovered in tissue-based studies are most likely to be
used for establishing individual prognosis or predicting
response to therapy when the presence of disease is
already known. It is therefore desirable for these studies
to focus on classifying disease subsets or establishing
molecular correlates of response in existing trials.
Markers discovered in serum-based studies are often
intended for early diagnosis, in which case it is
essential that future studies include subjects who are
at risk but have not yet been diagnosed with disease.
– It would be helpful to incorporate uniformly rigorous
statistical criteria in both design and analysis. There is a
wide variation in the types and sophistication of statis-
tical analysis employed in proteomic studies. It appears,
in many cases, that study size is based on availability of
samples or other resources, rather than explicit statistical
reasoning. The use of ‘‘fold-change’’ remains prevalent
as a criterion for ranking candidate biomarkers, although
there is seldom explicit justification.
– It would be fruitful to maintain an up-to-date and
searchable index of the lists of biomarkers obtained in
different studies. Proteomic studies generate vast
amounts of data; even a small study with 10–20
patients can generate tens of thousands of protein
abundance values. In this review, we have relied
primarily on the author’s own assessment of their
findings, as a comprehensive re-analysis of all of the
primary data in the cited studies is beyond our scope.
– Finally, it is essential that future studies focus not only
on identifying the disease-associated alterations in
proteins but also on determining the cellular functions
of the proteins identified, as well as the mechanistic
networks in which they participate. The biomarkers
identified experimentally should serve as entry points
for investigating the mechanisms of carcinogenesis and
tumor progression.
Despite the existing barriers to clinical translation, it is
important not to lose sight of the ultimate promise of
clinical proteomics in GI medicine. Standard diagnostic
procedures for GI diseases are largely based on clinical
data in combination with endoscopy, imaging examination,
histopathology, and immunohistology. Yet, we often
observe that individual patients sharing the same type of
disease, with the same histopathologic diagnosis, at an
identical stage, end up with different clinical outcomes
with respect to survival and treatment response. This
indicates that each patient’s disease may have a unique
constellation of molecular derangements [107].
In the future, clinical proteomics may provide a rational
basis for individualized therapy. Patients with a GI
malignancy could be identified early by screening serum or
other GI fluids. A tissue biopsy could then be analyzed for
a proteomic signature to establish prognosis, to select the
best targets for individualized therapy, and to predict
therapeutic responses and toxicities [108]. A recurrence
could be detected early by serum analysis, providing an
opportunity to alter the therapeutic regime. Using these
new tools, GI malignancies could become manageable
chronic diseases [109].
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